Latest UCB Stories
Romosozumab Currently in Phase 3 Clinical Development, Pivotal Data Expected in 2016 THOUSAND OAKS, Calif. and BRUSSELS, Sept.
- VIMPAT® (lacosamide) C-V approved in the U.S. as monotherapy in the treatment of partial-onset seizures in adults with epilepsy(1) BRUSSELS, Sept.
DUBLIN, Aug. 22, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S.
- Dermira obtains exclusive rights to develop Cimzia® in psoriasis in the US, Canada and the European Union BRUSSELS and REDWOOD CITY, Calif., July 3, 2014 /PRNewswire/ -- UCB, a global biopharmaceutical
ATLANTA, April 30, 2014 /PRNewswire/ -- Today, the U.S.
THOUSAND OAKS, Calif. and BRUSSELS, Jan.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.